Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 14/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GCG | P01275 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15026310 | 0.94 | TTK (0.39) | TTKCYP3A4KDM4ENPC1RAB9A | |
| SCHEMBL30715 | 0.91 | TTK (0.38) | TTKCYP3A4CDK2CDK9MAPK1 | |
| SCHEMBL30250 | 0.82 | MEN1 (0.40) | KDM4ENPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL29141 | 0.76 | NTRK1 (0.32) | MAPK1NTRK1 | |
| SCHEMBL10235010 | 0.75 | OPRK1 (0.36) | CYP3A4KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL595888 | 0.74 | NTRK1 (0.36) | KDM4ENPC1RAB9ASMN1; SMN2CDK2 | |
| SCHEMBL30002 | 0.72 | RIPK3 (0.35) | MAPK1NTRK1 | |
| SCHEMBL29902 | 0.71 | KDM4E (0.47) | TTKKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10239331 | 0.71 | MET (0.37) | KDM4ENPC1RAB9ASMN1; SMN2CDK2 | |
| SCHEMBL7883776 | 0.70 | NPC1 (0.36) | TTKCYP3A4KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703784-B2 | Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703784-B2 | Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2608668-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | Merck Sharp & Dohme Corp. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130150353-A1 | Fused Tricyclic Inhibitors of Mammalian Target of Rapamycin | MERCK SHARP & DOHME LLC | 2013-06-13 | — | — | US | disclosed |
| US-20130150353-A1 | Fused Tricyclic Inhibitors of Mammalian Target of Rapamycin | MERCK SHARP & DOHME LLC | 2013-06-13 | — | — | US | disclosed |
| WO-2012027234-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | SCHERING CORPORATION (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150353-A1 | Fused Tricyclic Inhibitors of Mammalian Target of Rapamycin | MTOR, RICTOR, RPTOR | TTK 542/4885CYP3A4 4621/4885KDM4E 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.